



## Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

Sohita Dhillon<sup>1</sup>

Published online: 6 February 2019  
© Springer Nature Switzerland AG 2019

**Correction to: Clin Drug Investig (2019)**  
<https://doi.org/10.1007/s40261-018-0741-2>

An Online First version of this article was made available online at <https://rd.springer.com/article/10.1007/s40261-018-0741-2> on 3 January 2019. An error was subsequently identified in the article, and the following correction should be noted:

Correction to Fig. 1 caption

The caption of Fig. 1, which previously read:

“**Fig. 1** Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. *E* oestrogen, *ER* oestrogen receptor, *HR* hormone receptor, *HER2* human epidermal growth factor receptor 2”

Should read:

“**Fig. 1** Inhibition of ER/HER2 cross-talk with neratinib plus endocrine therapy. *E* oestrogen, *ER* oestrogen receptor, *HR* hormone receptor, *HER2* human epidermal growth factor receptor 2. © Puma Biotechnology, 2018 (published with permission)”

---

The original article can be found online at <https://doi.org/10.1007/s40261-018-0741-2>.

---

✉ Sohita Dhillon  
demail@springer.com

<sup>1</sup> Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand